Abstract To investigate the effect of electro-acupuncture (EA) as a non-pharmacological intervention to prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain InventoryShort Form (BPI-SF), Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI-SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI-SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham-controlled trial of EA for prevention of taxane-induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN.
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling toxicity of cytotoxic chemotherapy [1, 2] . CIPN can cause treatment dose-reductions and discontinuation, leading to poor tumor control and worse prognosis [3] [4] [5] . Approximately 50 % of breast cancer patients receive taxane therapy, including paclitaxel and docetaxel, as large clinical trials have shown that adjuvant paclitaxel could effectively improve overall survival for women with node positive and high-risk node negative breast cancer [6] [7] [8] . Recent studies have shown that 60-70 % of patients treated with taxanes report CIPN symptoms [2, 9] , and 25-40 % have dose limiting CIPN [9, 10] . CIPN can resolve with cessation of chemotherapy, but often persists long term.
There are currently no effective drugs or modalities to prevent CIPN. Current CIPN guidelines recommend duloxetine as the only effective treatment for painful CIPN [11, 12] . Other medications prescribed to treat CIPN have shown limited efficacy, including tricyclic antidepressants [13, 14] , anticonvulsants [15, 16] , and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine [17] . Acupuncture is a therapeutic modality used to treat acute and chronic pain with a low side effect profile [18] . The physiologic mechanisms behind the analgesic effects of acupuncture are unclear, but likely involve the release of endogenous opiates and neurotransmitters [19] . In cancer patients, acupuncture and transcutaneous electrical nerve stimulation (TENS) have been used to treat cancer pain with demonstrated efficacy [20, 21] . Electroacupuncture (EA) involves acupuncture needles attached to an electro-stimulator device that generates a low electrical current between the needles. Recently, studies have shown that acupuncture with and without electrical stimulation may effectively relieve CIPN symptoms [12, 22] . Administering EA during chemotherapy to prevent CIPN symptoms has not been tested.
We conducted a randomized sham-controlled trial to investigate the effect of EA as a non-pharmacological intervention to prevent or reduce CIPN in women with stage I-III breast cancer receiving adjuvant or neo-adjuvant paclitaxel weekly for 12 cycles.
Methods Participants
Between February 2011 and October 2014, women age [21 years with a history of stage I-III breast cancer scheduled to receive 12 weeks of weekly adjuvant or neo-adjuvant paclitaxel were recruited from Columbia University Medical Center's (CUMC) breast oncology clinic. Patients who reported prior treatment with acupuncture in the previous 12 months and/or a history of the following medical conditions were excluded: diabetic neuropathy or other neuropathic pain conditions; inflammatory, metabolic, or neuropathic arthropathies; current narcotic use; severe coagulopathy or bleeding disorder; dermatological disease within acupuncture needling area; and use of a pacemaker. Patients provided written informed consent. The study was approved by the institutional review board at CUMC and registered at ClinicalTrials.gov (NCT01163682).
Baseline data collection
At baseline, participants completed questionnaires on demographic and clinical characteristics. Breast cancer characteristics and chemotherapy treatment data were abstracted from the electronic medical record. Neuropathic symptoms were assessed using a range of subjective and objective assessment tools. The Brief Pain Inventory-Short Form (BPI-SF) used a 0-10 scale to rate the worst pain on the day of interview [23] . The Functional Assessment of Cancer Therapy-Taxane (FACT-TAX) assessed quality of life domains (physical well-being, social well-being, emotional well-being, functional well-being) and neurotoxicity using an 11-item neurotoxicity score (FACT-NTX) [24] . The Neuropathic Pain Scale (NPS) assessed ten distinctive aspects of peripheral neuropathic pain conditions using a 0-10 scale [25] . We assessed neuropathy pain using the NPS-10 (includes all ten items in the NPS), NPS-8 (includes all items except for the ''intense'' and ''unpleasant'' pain), and NPS-4 (only includes the ''sharp,'' ''hot,'' ''dull,'' and ''deep'' pain) scores. Development of sensory neuropathy was measured via changes in vibratory perception threshold using a handheld Model 2291L biothesiometer (Bio-Medical Instrument Company, Newbury, OH) [26] . Development of motor neurologic dysfunction was assessed via the Grooved Pegboard test Model 32025 (Lafayette Instrument Evaluation, Lafayette, IN), which measures hand eye coordination and fine motor skills [27] .
Randomization and blinding
After baseline data collection was completed and prior to the initiation of taxane therapy, participants were randomized to receive either 12 weeks of weekly EA or 12 weeks of weekly sham EA (SEA). Participants, study staff, and clinicians were blinded to study assignment; only the acupuncturist, study statistician and a study coordinator with no participant contact were aware of randomization assignment.
Electro-acupuncture and sham electro-acupuncture protocols
Weekly EA and SEA visits were scheduled within 2 days of the weekly chemotherapy infusion. All acupuncture sessions were conducted within the CUMC breast oncology clinic.
Electro-acupuncture protocol
The EA point protocol was developed based on a standard Traditional Chinese Medicine (TCM) protocol for qi and xue deficiency and stagnation and informal practitioner query. Three independent acupuncturists were queried about their standard practice for CIPN prevention and treatment and were asked to provide feedback on the proposed standardized study acupuncture protocol. Each practitioner had a minimum of 5 years of clinical experience treating oncology patients. The final point protocol for body, lower limb, and upper limb acupuncture points is shown in Table 1 . All participants received all points. Stainless steel disposable acupuncture needle (MAC Co. Tian Jin Haing Lim Sou Wan Medical Instrument Co., Ltd. Distributed by Roslyn Heights, NY, USA, diameter 32G 9 .25 mm) were inserted into the skin to the appropriate depth (approximately 3-4 mm) needed to elicit de qi. De qi is the term used to describe a needle sensation characteristic of acupuncture needling described as a dull or achy sensation of soreness. Selected acupuncture points were attached to 2 leads connected to an electrostimulator (KWD-808 Multi-Purpose Transcutaneous Simulator Device, Great Wall Brand, Distributed, NY, NY) that generated 2 Hz of mixed pulsatile intervals for a total of 30 min. Needles not attached to the electro-stimulator were manipulated manually to elicit de qi once during the treatment.
Sham electro-acupuncture protocol
Patients in the control arm received weekly SEA using Park Sham collapsible needles (Dongbang AcuPrime, Exeter, United Kingdom) that touch but do not penetrate the skin [28] . The sham point prescription did not include any true acupuncture points and is shown in Table 1 . The electro-stimulator was attached to the needles, the acupuncturist turned on the machine to a non-transmitting setting for 30 min, and the acupuncturist touched the collapsible acupuncture needs to simulate the manipulation of the needles.
Follow-up data collection
At weeks 6, 12, and 16, participants repeated in-person subjective and objective assessments of neuropathy. At week 16, participants were asked if they thought they received EA or SEA.
Study endpoints and statistical methods
Evaluable subjects were defined as those who signed consent, completed the baseline questionnaire and at least one of the follow-up questionnaires, and completed at least 3 weeks of acupuncture. The a priori primary endpoint was the difference in neuropathic pain between the two arms as measured by the Brief Pain Inventory-Short Form (BPI-SF) mean worst pain score at 12 weeks. The BPI-SF worst pain score uses a 0-10 scale for subject ratings. A priori increase of C2 points on the BPI-SF worst pain score and reduction of C5-points on the FACT-NTX were considered to be a clinically meaningful change. Sample size estimates were based on a two-arm normal design. Assuming a 2-point difference in BPI-SF worse pain score to be clinically significant and a standard deviation of the average difference to be 2, and using a twosided test with a = .05, a sample size of 50 patients (25 per arm) was estimated to provide 94 % power to detect a clinically meaningful change in BPI-SF worst pain score between arms. For the intention-to-treat analyses, twosample t tests were used to compare between-group differences and paired t tests for within-group means for the EA and SEA groups in BPI-SF worst pain score. Generalized estimating equations (GEE) with the unstructured working correlation matrix and identity link function tested the interaction between treatment and visit on BPI-SF, adjusted for baseline scores and number of received taxane cycles. In multivariable analyses, logistic regression analyses of clinically meaningful changes in BPI-SF were adjusted for baseline BPI-SF worst pain score and number of received taxane cycles. Confidence intervals and P-values were estimated using the robust standard error. Secondary objectives were to determine differences in FACT-NTX, FACT-TAX, NPS, biothesiometer test scores, and grooved pegboard test scores. All analyses were conducted utilizing R statistical software (version 3.2.2, https://cran.r-project.org/).
Results

Accrual, eligibility, and evaluability
Between November 2009 and November 2012, a total of 180 subjects were screened and 63 were randomized (n = 31, EA; n = 32, SEA). Figure 1 shows 
Participant characteristics
The mean age of participants was 50 years (SD = 11). Participants were diverse in race/ethnicity: 25 % were nonHispanic white, 25 % were African American, and 43 % were Hispanic. Nearly half (48 %) had received doxorubicin and cyclophosphamide (AC) prior to taxane chemotherapy. There were no differences between groups in demographic or clinical characteristics (Table 2) .
Chemotherapy and intervention adherence
There were no differences in taxane treatment adherence between arms as assessed by cycles received or in dose limitations due to CIPN symptoms (Table 2 ). There were no differences between groups in acupuncture session attendance (Table 2 ). In the EA arm, participants received an average of 10 (SD = 3) sessions, which was similar to the SEA arm, which received an average of 10 (SD = 4) sessions (P = .80).
Blinding
The majority of patients (87 %) believed that they received true electro-acupuncture regardless of the actual treatment received (Table 2 ). There was no between-group difference in effectiveness of blinding (SEA: 90 % vs. EA: 83 %, P = .67).
BPI-SF worst pain score
In between-group analyses, there were no differences in worst pain scores at 6 and 12 weeks. However, at 16 weeks, while the worst pain score reverted to baseline level in the SEA arm, it continued to worsen in the EA arm (P = .03; Table 3 ; Fig. 1a) . In GEE analyses of interactions between treatment and visits, the increase in the worst pain score at 16 weeks was 1.62 points greater in the EA arm than in the SEA arm (P = .04; Table 4 ), suggesting that patients receiving EA experienced more increases in pain symptoms after the intervention.
FACT-NTX subscale score
In between-group analyses, there were no differences in FACT-NTX at 6, 12, and 16 weeks. In logistical regression analyses examining a clinically meaningful change in scores, there was a trend towards increased pain at week 16 (OR = 1.25, 95 % CI .97-1.62).
NPS, FACT-TAX, biothesiometer, and grooved pegboard
In between-group analyses, at week 16, participants in the EA arm reported worse pain in the NPS-4 scale (P = .03) ( Table 3 ; Fig. 2 ). There were no differences between groups in the FACT-TAX, biothesiometer or grooved pegboard tests (Online Fig. 1 ).
Adverse events
One adverse event was reported, which was a grade 1 acupuncture needle site reaction with discomfort, minor swelling, and bruising after acupuncture needle withdrawal. Abbreviations: BPI-SF Brief Pain Inventory-Short Form; FACT-NTX neurotoxicity component of Functional Assessment of Cancer TherapyTaxane scale; FACT-TAX Functional Assessment of Cancer Therapy-Taxane scale; NPS neuropathic pain scale; EA electro-acupuncture; SEA sham electro-acupuncture; SD standard deviation * Paired t test was used to compare the mean scores at each follow-up and baseline within each treatment group. Two-sample t test was used to compare the mean scores and mean change from baseline between treatment groups at each follow-up ** Statistically significant, P value \.05 a BPI-SF worst pain: higher score indicates greater pain (range 0-10) b FACT-NTX subscale score (range 0-44) and FACT-TAX total score (range 0-172): higher score indicates greater quality of life c NPS: higher score indicates greater neuropathy. The raw score ranges 0-10, the standardized scores were used for analysis. NPS-4 reflects nonperipheral pain mechanisms. Normalized to 0-100
Discussion
In this randomized sham-controlled trial of EA to prevent CIPN in women receiving taxane-based chemotherapy for early stage breast cancer treatment, we did not observe differences in pain or neuropathy symptoms between treatment arms at 12 weeks. Unexpectedly, compared to SEA subjects, women on EA experienced greater increase in pain at 4 weeks after taxane completion. No differences were observed between groups with regard to taxane adherence. A number of case reports suggested that acupuncture may be effective at reducing pain and improving nerve conduction studies in cancer patients with CIPN [29] [30] [31] ; however these studies suffer from lack of a control group. In a retrospective case series study (n = 18), Donald et al. identified that 84 % of patients attending six sessions of acupuncture reported improved CIPN symptoms [32] . In a recent single arm trial (n = 27), Bao et al. reported that 10-weeks of acupuncture was significantly associated with reducing pain and improving neuropathy symptoms in multiple myeloma patients with bortezomib-induced peripheral neuropathy [33] . A randomized controlled trial among patients with paclitaxel or oxaliplatin-induced peripheral neuropathy (n = 64) showed that sensory nerve disorder was improved in 67 % of patients receiving acupuncture compared to 40 % of patients who received a form of vitamin B 12 [34] . These studies suggest that acupuncture may serve as an effective treatment for CIPN symptoms, but have limited efficacy on pain in cancer patients. A number of ongoing clinical trials are currently investigating the role of acupuncture in the treatment (NCT02129686, NCT02615678) and prevention (NCT02615678) of taxane-induced peripheral neuropathy in breast cancer patients.
It is important to recognize that our findings are not directly comparable with previous reports, as our trial focused on the prevention of CIPN, whereas other studies focused on the management of post-chemotherapy CIPN. A trial by Lu et al. is somewhat comparable [35] . The trial investigated the effect of EA on quality of life outcomes in ovarian cancer patients (n = 21) undergoing chemotherapy and found that patients in the EA arm reported worse peripheral neuropathy symptoms compared to the SEA arm. However, the study assessed peripheral neuropathy using the Quality of Life Questionnaire-Ovarian Module-28 Item (QLQ-OV28), which assesses tingling and numbness in the hands and feet via 2 items. This measure is less comprehensive compared to the 11-item FACT-NTX subscale used in our study. Furthermore, differences in cancer Another notable and puzzling finding of our trial was the post-intervention worsening of pain symptoms in the EA arm, which was similarly reported in Chen et al.'s RCT of EA versus SEA in reducing pancreatic cancer pain [36] . The mechanism of such pain rebound is unknown. It is possible that the electrical stimulation component of the EA may have caused CIPN symptoms, and therefore it is possible that EA may not be as effective and safe as traditional acupuncture without electrical stimulation. In addition, patients without prior acupuncture treatment may experience stronger stimulation or even discomfort from EA compared to traditional acupuncture [37] . Therefore, other forms of acupuncture should be evaluated for the prevention of CIPN. It is also possible that there was higher response expectancy in the SEA arm, which led to better pain management. In our study, though it was not a statistically significant difference, a slightly larger percentage of patients in the SEA arm believed that they received true acupuncture, compared to the EA arm. A recent study suggested that higher response expectancy may moderate better acupuncture response in patients receiving sham acupuncture, but not in patients receiving true acupuncture [38] . Therefore, it is possible that in our study a greater placebo effect may have led to better pain relief in the SEA arm.
The mechanism by which acupuncture may affect CIPN is unclear. Acupuncture may relieve pain through the release of endogenous opiates and neurotransmitters [19] . An in vitro study showed that diabetic mice who received EA for 4 weeks had better nerve conduction studies and increased tactile threshold compared to the diabetic mice that did not receive EA [39] . In a retrospective study, patients with unspecified peripheral neuropathy who electively received acupuncture for pain reported reduced pain symptoms and improved nerve conduction studies [40] . Similarly, in a small non-randomized clinical trial in patients with chronic diabetic neuropathy, acupuncture relieved pain symptoms in 21 % of patients, although the reduction in pain intensity was short term [41] . These studies suggest that acupuncture may not only relieve pain but may also be protective against the development of neuropathy. More recent studies suggest acupuncture mediates pain via inhibition of secretion of pro-inflammatory cytokines, including interleukin (IL)-1b, IL-6, IL-17, and tumor necrosis factor (TNF)-a [42, 43] . The major strengths of our study are the use of a standardized EA and SEA protocol and the use of validated self-reported and objective outcome measures in a diverse population of breast cancer patients. We collected extensive data on patient information and chemotherapy dosage, allowing us to account for chemotherapy dosage in evaluating acupuncture effectiveness and examine chemotherapy adherence and dose-limiting between arms for any potential confounding. An additional strength was the heterogeneous race/ethnicity of the study population, which increases the generalizability of the findings. Though retention in the study was good (90 % at 12 weeks), we did lose some patients to follow up, which could bias the results. Similarly, there was some non-adherence to the intervention with 48 % of patients not attending at least 1 of the 12 sessions. Failure to attend the acupuncture sessions was primarily due to logistical issues with attending weekly acupuncture sessions in Manhattan. Future studies should test acupuncture protocols that are feasible given the study population.
Our RCT of electro-acupuncture versus sham electroacupuncture in preventing taxane-induced neuropathy among breast cancer patients did not identify a protective effect of acupuncture on CIPN symptoms over the course of chemotherapy. Unexpectedly, subjects receiving electroacupuncture had a slower recovery in CIPN symptoms compared to subjects receiving sham electro-acupuncture. Future studies should focus on electroacupuncture or other forms of acupuncture for the treatment as opposed to prevention of CIPN. In addition, future studies should further investigate the worsening of pain in patients receiving EA and the possible role of outcome expectations in acupuncture studies.
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